LUNG Pulmonx

Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference

Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference

REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT / 11:30am ET.

Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at .

About Pulmonx

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit . For more information on the company, please visit .

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact

Brian Johnston

Gilmartin Group



EN
29/07/2021

Underlying

LUNGPulmonx

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pulmonx

 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth qua...

2h / 1m 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Announces Closing of up to $60 Million Credit Facility Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors. The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company’s exi...

2h / 2m 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results ...

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on ...

February 20, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TPVG TRIPLEPOINT VEN...
KVHI KVH Industries ... ... (+20)

InsiderInsights.com Daily Ratings Report: December 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
MGM MGM RESORTS INTERNATIONAL
MIDD THE MIDDLEBY CORPORATION
HCAT HEALTH CATALYST
AVTR AVANTOR
ORIC INC.
MRVI ORIC PHARMACEUTICALS
LUNG MARAVAI LIFESCIENCES HOLDINGS
NRDY PULMONX
ABSI NERDY INC.
GAM ABSCI CORP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
MXF SPRUCE POWER HOLDING CORP
VG THE MEXICO FUND
SINT INC.
SEVN VENTURE GLOBAL INC.
SINTX TECHNOLOGIES INC.
SEVEN HILLS REALTY TRUST
12/10/25 December 10, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(...

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) for an aggregate of 1,625,000 shares of Pulmonx’s common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx’s Chief Financial Officer and Chief Oper...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch